Summary.-The lethal effect of high-dose melphalan in mice could be offset by pretreatment with cyclophosphamide, cytosine arabinoside or low-dose melphalan. The reason for improved survival is unclear. Although animals given high-dose melphalan died with symptoms of gut death, in only one instance, that with low-dose melphalan itself, did pretreatment protect the intestinal epithelium as measured by the microcolony assay. A small enhancement in the recovery of the haemopoietic tissue in pretreated animals was noted, although this on its own is unlikely to explain the phenomenon. Experiments in tumour-bearing mice showed that pretreatment with cyclophosphamide did not reduce the toxicity of melphalan to the Lewis lung carcinoma.
SEVERAL biniary combinations of cytotoxic agents have been reported to have less than the expected toxicity on normal tissues in mice and rats. These combinations generally take the form of a small dose (the pretreatment or priming dose) followed by a large challenge dose of the same (Jeney et al., 1968; Rose et al., 1975; Millar and McElwain, 1978) or different cytotoxic agent Jeney et al., 1968; Schmidt et al., 1970 : Millar et al., 1975 Millar and Hudspith 1976; Millar et al., 1978) .
In this communication, the effect of various pretreatments in reducing the toxicity of a large dose of melphalan (Melph) in mice is reported. The reaction of the clonogenic cells in marrow and intestinal epithelium to a combination of cyclophosphamide (Cyclo) and Melph is investigated. Bearing in mind the importance of normal-tissue-sparing combinations in cancer chemotherapy, the effectiveness of the sparing combination of Cyclo and Melph on a murine tumour, the Lewis lung carcinoma is also reported.
AIATERIALS AND AIETHODS
Aninmals.-8-10-week-old CBA or C57BL male mice were used in survival studies, w'ith never less than 10 animals per point. CBA mice were used in normal-tissue toxicity studies, whereas C57BL mice were used in experiments involving the Lewis lung carcinoma. Mice ranged in weight between 22 and 27 g at the start.
Drugs.-All drugs w%Nere administered i.p.
Pure cyclophosphamide monohydrate (Cyclo) (Endoxana, Koch-Light Ltd) was used. It was dissolved in saline, as was cytosine arabinoside. (AraC) (Cytosar, Upjohn Ltd). Melphalan (Melph) (Alkeran, Burroughs Wellcome & Co.) was first dissolved in 1 ml of 2o% (v/v) acid alcohol and then in saline to the required concentrations. All solutions were prepared shortly before use.
Haemopoietic stem-cell assay.-Stem cells of the femoral marrowv were assayed using the technique of Till and McCulloch (1961) . The procedure for measuring peripheral-blood leucocyte and granulocyte levels has been reported elsewhere (Millar and Hudspith, 1976 ). There were 5 donor animals per group and never less than 8 animals in recipient groups or groups used to study peripheral leucocyte recovery.
Studies on the intestinal epitheliumn.-Crypt regeneration in the jejunum after Melph treatment was assessed by a method similar to the microcolony technique described by Withers and Elkind (1970) Lewis lung tumour.-Lewis lung tumours were grown i.m. and treated in situ with Melph. Some groups of mice received 50 mg/ kg Cyclo 2 days before the Melph. Either 18 h or 72 h after the Melph treatment, single-cell suspensions were made from the tumours, and the number of surviving clonogenic cells was assessed using the lung colony assay (Steel and Adams, 1975) . The lung colonies were derived from surviving clonogenic tumour cells, and the fraction of surviving clonogenic cells per tumour was calculated, as has previously been described (Stephens and Peacock, 1977) .
RESULTS

Survival experiments
A dose of 20 mg/kg Melph killed 9/10, correlation between crypt survival and animal survival (Fig. lc) .
Survival of marrow stem cells after melphalan The survival of marrow stem cells (CFU-S) after various doses of Melph in normal animals and in animals given 50 mg/kg Cyclo 2 days before, is shown in Fig. 3 . There is no evidence that pretreatment with Cyclo altered the sensitivity of the stem cells to Melph. The small vertical separation between the lines indicates the effect of the 50 mg/kg Cyclo pretreatment.
Recovery ofmarrow stem cells after melphalan
The recovery of bone marrow stem cells after 15 mg/kg Melph was followed in otherwise normal animals and in animals given 50 mg/kg Cyclo 2 days before (Fig.  4) . This dose of Melph allowed all control animals to survive the duration of the experiment. It can be seen that, although the depression is slightly greater in animals that received the pretreatment, recovery took place at a greater rate. At Day 6, for instance, the number of stem cells in pre- In work with radiation, with challenge doses up to 1000 rad when marrow is the critical tissue, we have noted that the response of marrow stem cells was the same in normal and pretreated animals, and that recovery, when it got under way in each situation, proceeded at the same rate (Millar et al., 1978) . The difference was in the time at which recovery began. In pretreated animals there was little or no post-irradiation lag, recovery beginning promptly after irradiation (Smith et al., 1968; Hanks and Ainsworth, 1967; Brecher et al., 1967; Millar et al., 1978) . This suggests that the pretreatment dose prepared the system for the challenge dose, and recovery began promptly after the challenge dose.
At higher doses of radiation the intestinal epithelium becomes the critical tissue. Pretreatment with Ara C 12 h before irradiation reduces the toxicity of the radiation on this tissue (Boarder, 1976) . In this situation there appears to be a reduction in the radiosensitivity of the tissue.
Pretreatment with a small dose of Cvclo will offset lethality of an otherwise lethal Cyclo dose (Millar and McElwain, 1978 (Millar et al., 1978) in which enhanced survival of marrow improved the survival of irradiated mice, has shown that an interval of about 8 days is required. for improved survival of stem cells to be reflected in increased peripheral leucocyte number.
Although the results of the survival experiments could not be established with great accuracy, as large numbers of animals were not used, it appeared from Fig.  1 that, as a rule, pretreatment 2 days before a challenge with high-dose Melph provided the best survival, and this was the case whether Cyclo, Aia C or low-dose Melph was used as the pretreatment. This is consistent Nith the timing where radiation was used as the challenge, and various cytotoxic agents offset lethality (Millar et al., 1978) .
In conclusion, a similar type of recovery to that studied in the marrow (Millar et al., 1978) in pretreated animals cannot be shown to operate in the gut by our present methods. Other mechanisms, which might involve interaction between gut and marrow, must remain speculative. It is noteworthy that Lewis lung tumour tissue was not spared by Cyclo pretreatment, and the potential therapeutic advantage of pretreatment before large-dose challenge should therefore be stressed. Pilot studies in the clinic are in progress and have so far yielded encouraging results.
